Summit Therapeutics Inc. (SMMT) Daily Stock Prediction

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridium difficile infection (CDI). The company’s lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. Summit Therapeutics Inc. was founded in 2003 and is based in Cambridge, Massachusetts.

Sector:

Healthcare

Industry:

Biotechnology

Address:

Summit Therapeutics Inc. One Broadway 14th Floor Cambridge MA 02142 United States

Website:

http://www.summitplc.com

Phone:

617-514-7149